BYD India Unveils its Luxury Electric Sedan BYD Seal & Launches BYD ATTO 3 Limited Edition at Auto Expo 2023
12.1.2023 17:02:00 EET | Business Wire | Press release
BYD, the global leading new energy vehicle (NEV) manufacturer, presented its new luxury model BYD Seal and the limited edition of BYD ATTO 3 in its iconic color Forest Green at the Indian Auto Expo 2023. BYD Seal, whose sales have exceeded 50,000 within 5 months in China, is planned to be launched in India by Q4 2023. As the All-New e6 and BYD ATTO 3 are already available in the local market, BYD Seal will be the third passenger EV released in India within two years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005445/en/
Speech by Sanjay Gopalakrishnan, Senior Vice President of Electric Passenger Vehicles, BYD India (Photo: Business Wire)
At the Auto Expo 2023, BYD’s display space is sectioned into 4 zones, which showcase not only its current and new vehicle products but also technological innovations that substantially enhance the performance and safety of vehicles. These newly-unveiled products and innovation displays echo the Indian-specific theme at the convention: Technological Innovations For A Better Life.
BYD SEAL
BYD Seal is one of BYD’s latest luxury sedans equipped with its renowned EV platform (e-Platform 3.0) and revolutionary ultra-safe Blade Battery. Also, it is the first vehicle equipped with CTB (cell to body) technology, substantially upgrading the vehicle’s safety, stability, and handling, giving the vehicle an overall finer performance.
CTB-supported BYD Seal can withstand the 50-ton heavy-duty truck rolling test. Via the integration of battery and body, the torsional stiffness of the whole vehicle has doubled to above 40,500 N.m/°. The safety of the interior structure of the vehicle is increased by 50% for the front impact and by 45% for the side impact. Also, as CTB technology makes it possible for BYD Seal to have an ideal 50:50 axle load distribution, the vehicle passed the moose test at a record speed of 83.5km/h. With its low-lying design, the aero drag coefficient reached as low as 0.219cd, helping BYD Seal hit 100 km/h in 3.8 seconds. The model also has an ultra-long range of up to 700 km on a single charge, reducing the range anxiety of EVs.
BYD ATTO 3 Limited Edition
At the event, the Limited Edition of BYD ATTO 3 in the exclusive color of Forest Green, also adopts the e-Platform 3.0 and the ultra-safe Blade Battery. Only 1,200 units of this Limited Edition will be available in India at Rs. 34.49 lakhs (ex-showroom).
BYD ATTO 3, with an NEDC-certified range of 480 km and ARAI test range of 521 km, was launched in India in November 2022 for Rs. 33.99 lakhs and garnered 1,500 bookings to date, gaining good traction among customers. BYD ATTO 3 received a five-star safety rating from Euro NCAP, Europe’s leading independent safety assessment program. The E-SUV boasts an 8-year or 1.6 lakh kilometer (whichever comes earlier) warranty for the battery and a similar 8-year or 1.5 lakh kilometer warranty for the motor and motor controller. Besides, BYD offers a 6-year or 1.5 lakh kilometer basic warranty.
Sanjay Gopalakrishnan, Senior Vice President of Electric Passenger Vehicles of BYD India, said: “The Indian Auto Expo is an extremely significant platform for us, and we are pleased to be able to showcase our products and technologies through our technological innovations for a better life. With the unveiling of the electric luxury sedan BYD Seal, the launch of the Limited Edition of BYD ATTO 3, and the display of the Blade Battery, e-Platform 3.0, we resonate our commitment to contribute to the growth of the Indian electric vehicle segment with EV technologies.”
Within a year, BYD has expanded its network to 24 showrooms across 21 cities in India and will double the presence to 53 showrooms within 2023. “Next year, we plan to sell 15,000 units of BYD ATTO 3 and All-New e6 with a long-term vision to take up 40% of the Indian EV market by 2030. The bookings of BYD ATTO 3 have been encouraging, and we are all set to start the first deliveries from January 2023,” added Mr. Gopalakrishnan.
In 2022, BYD's cumulative sales of passenger vehicles were over 1.86 million units, a year-on-year increase of 155.1%. So far, BYD has sold more than 3.37 million new energy vehicles. With its expanding global presence, BYD is working towards its initiative of “Cool the Earth by 1 °C.”
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, the DM-i and DM-p hybrid technology, the e-Platform 3.0, and the CTB technology. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on the EV shift and has remained top of new energy passenger vehicle sales in China for 9 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005445/en/
Contact information
Asia-Pacific: Mia Gu, pr@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: José Miranda, jose.miranda@byd.com
tel: +56 9 96443906
Brazil: Adalberto Maluf, adalberto.maluf@byd.com tel: +19 3514 2554
Africa: Nikki Li, li.namin@byd.com tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom